C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial

The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study)....

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 128; no. 4; p. 576
Main Authors:	Jaffe, Glenn J, Westby, Keith, Csaky, Karl G, Monés, Jordi, Pearlman, Joel A, Patel, Sunil S, Joondeph, Brian C, Randolph, John, Masonson, Harvey, Rezaei, Kourous A
Format:	Journal Article
Language:	English
Published:	United States 01.04.2021
Subjects:	Aged Aged, 80 and over Aptamers, Nucleotide - therapeutic use Complement C5 - antagonists & inhibitors Complement Inactivating Agents - therapeutic use Double-Blind Method Female Fluorescein Angiography Follow-Up Studies Geographic Atrophy - diagnosis Geographic Atrophy - drug therapy Geographic Atrophy - physiopathology Humans Intravitreal Injections Macular Degeneration - diagnosis Macular Degeneration - drug therapy Macular Degeneration - physiopathology Male Prospective Studies Visual Acuity - physiology GATHER1 GATHER2 geographic atrophy Zimura Complement dry avacincaptad pegol age-related macular degeneration C5 inhibitor
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!